SCHEMBL21361441

SCHEMBL21361441

COc1ccc(N2CCN(C(C)C)CC2)cc1F

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
PKM P14618 2/20 0.49
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
ACVR1 Q04771 4/20 0.47
TGFBR1 P36897 3/20 0.47
KCNH2 Q12809 1/20 0.47
BMPR1B O00238 1/20 0.46
BMPR1A P36894 1/20 0.46
ACVR1B P36896 1/20 0.46
ACVRL1 P37023 1/20 0.46
TNIK Q9UKE5 1/20 0.46
TLR9 Q9NR96 4/20 0.46
TLR7 Q9NYK1 4/20 0.46
TLR8 Q9NR97 3/20 0.46
ACACB O00763 1/20 0.45
ALK Q9UM73 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
FYN P06241 1/20 0.43
SUV39H2 Q9H5I1 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14922721 0.83 SIRT6 (0.55) MAPTKDM4EALDH1A1ACVR1TGFBR1
SCHEMBL2206359 0.82 ALDH1A1 (0.49) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL17241036 0.81 ALDH1A1 (0.54) MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL1911903 0.80 TGFBR1 (0.51) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL23102236 0.79 KDM4E (0.50) MAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2209498 0.79 ALDH1A1 (0.49) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL310368 0.79 ALDH1A1 (0.49) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL20995233 0.78 KDM4E (0.51) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL22171249 0.78 MAPT (0.51) MAPTPKMKDM4EALDH1A1ACVR1
SCHEMBL29374099 0.78 KDM4E (0.51) MAPTPKMKDM4EALDH1A1ACVR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3765447-B1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2023-07-12 EP disclosed
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors KEZAR LIFE SCIENCES (US) 2023-02-14 US disclosed
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2021-03-18 US disclosed
WO-2019178510-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS KEZAR LIFE SCIENCES (US) 2019-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11578055-B2 Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors SEC61B, SEC61A1, SEC61G MAPT 3927/4885PKM 4329/4885KDM4E 4672/4885
US-20210078974-A1 TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G MAPT 4113/4885PKM 4298/4885KDM4E 4717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.